<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.4'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//pharminent.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://pharminent.com/fda-approves-sanofis-infilbray-for-gaucher-disease-type-3/</loc>
  <lastmod>2026-11-20T12:45:38Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>FDA approves Sanofi&amp;#039;s Infilbray for Gaucher disease type 3</news:title>
   <news:publication_date>2026-11-20T12:45:38Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-november-18-2026/</loc>
  <lastmod>2026-11-19T20:30:12Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • November 18, 2026</news:title>
   <news:publication_date>2026-11-19T20:30:12Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-november-18-2026/</loc>
  <lastmod>2026-11-19T20:29:59Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Manufacturing Intelligence • Weekly Digest • November 18, 2026</news:title>
   <news:publication_date>2026-11-19T20:29:59Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/strategic-news-watch/strategic-news-watch-november-19-2026/</loc>
  <lastmod>2026-11-19T20:29:42Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Strategic News Watch • November 19, 2026</news:title>
   <news:publication_date>2026-11-19T20:29:42Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/pfizer-signs-2-6b-in-vivo-car-t-deal-with-starna/</loc>
  <lastmod>2026-11-19T12:45:52Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Pfizer signs $2.6B in vivo CAR-T deal with Starna</news:title>
   <news:publication_date>2026-11-19T12:45:52Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/strategic-news-watch/strategic-news-watch-november-18-2026/</loc>
  <lastmod>2026-11-18T18:02:14Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Strategic News Watch • November 18, 2026</news:title>
   <news:publication_date>2026-11-18T18:02:14Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pharminent.com/fda-approves-berens-lembaz-for-niemann-pick-disease-type-c/</loc>
  <lastmod>2026-11-18T12:45:46Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Pharminent</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>FDA approves Beren&amp;#039;s Lembaz for Niemann-Pick disease type C</news:title>
   <news:publication_date>2026-11-18T12:45:46Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
